Brain Insulin Resistance and Development of Alzheimers Disease

脑胰岛素抵抗与阿尔茨海默病的发展

• 批准号: 9904967
• 负责人: MARK Andrew ESPELAND
• 金额: $ 37.36万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-07-01 至 2021-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9904967
• 关键词: AKT1 gene; AKT2 gene; AKT3 gene; Administrative Supplement; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Alzheimer’s disease biomarker; Amyloid beta-Protein; Antibodies; Binding; Biological Markers; Biological Sciences; Biometry; Blood; Blood specimen; Bovine Serum Albumin; Brain; Brain region; Buffers; Calcium; Case-Control Studies; Cells; Centrifugation; Cerebral cortex; Clinical Trials; Cognition; Cognitive; Complex; Data; Dementia; Development; Diabetes Mellitus; Elderly; Energy Intake; Excision; Exposure to; GLUT-3 protein; GLUT4 gene; Genomics; Glucose; Glycine; Goals; Gonadal Steroid Hormones; Health; Hippocampus (Brain); Hour; Human; IRS1 gene; Impaired cognition; In Vitro; Incubated; Inflammation; Insulin; Insulin Receptor; Insulin Resistance; Link; Magnesium; Magnetic Resonance Imaging; Maintenance; Measures; Memory; Metabolic; Methods; Molecular; Mus; Neural Cell Adhesion Molecule L1; Neurons; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Overweight; Participant; Pathology; Pathway interactions; Patients; Performance; Peripheral; Phosphoric Monoester Hydrolases; Phosphoserine; Physical activity; Plant Resins; Plasma; Population; Precipitation; Protease Inhibitor; Proteins; Publishing; Randomized Controlled Clinical Trials; Research Personnel; Resistance development; Risk; Role; SLC2A1 gene; Saline; Sampling; Sepharose; Signal Pathway; Skeletal Muscle; Streptavidin; Surface; Suspensions; Symptoms; System; Temperature; Testing; Thromboplastin; Time; Tissues; Transcript; Tyrosine; abeta accumulation; adjudicate; aged; angiogenesis; brain pathway; cell type; cerebral atrophy; cognitive development; cognitive function; cognitive performance; cohort; cost effective; design; euglycemia; exosome; improved; indexing; inhibitor/antagonist; insulin sensitivity; insulin signaling; intercellular communication; intravenous administration; lifestyle intervention; mild cognitive impairment; mind body interaction; multidisciplinary; nanoparticle; phosphatase inhibitor; preservation; relating to nervous system; specific biomarkers; targeted biomarker; tau Proteins; weight loss intervention

Project Summary R01 AG058571 Type 2 diabetes, characterized by insulin resistance in peripheral tissues such as skeletal muscle, increases AD risk. However, it is unclear whether there is a similar, or stronger, relationship between insulin resistance in the brain and AD. The goal of the proposed administrative supplement to Look AHEAD-MIND, while within the original scope, is to further unravel molecular pathways linking the intensive lifestyle intervention to the development of cognitive impairment by examining neural-derived blood exosome biomarkers for brain insulin resistance and Alzheimer's disease (AD) pathologies.

项目摘要R01 AG058571 2型糖尿病，其特征是外周组织中的胰岛素耐药性，例如骨骼肌， 增加广告风险。但是，目前尚不清楚是否存在类似或更牢固的关系 大脑和AD中的胰岛素抵抗。提议的行政补充的目标是 提前的虽然在原始范围内，但要进一步揭示连接的分子途径 通过检查神经衍生的认知障碍发展的强化生活方式干预 血液外泌体生物标志物用于脑胰岛素抵抗和阿尔茨海默氏病（AD）病理。